title: Invasive Aspergillosis in Hematological Patients.
abstract: Invasive aspergillosis (IA) is still one of the leading causes of morbidity and mortality in hematological patients, although its outcome has been improving. Prolonged and profound neutropenia in patients receiving intensive chemotherapy for acute leukemia and stem cell transplantation is a major risk factor for IA. Allogeneic stem cell transplant recipients with graft-versus-host disease and corticosteroid use are also at high risk. Management in a protective environment with high efficiency particular air (HEPA) filter is generally recommended to prevent aspergillosis in patients with prolonged and profound neutropenia. Antifungal prophylaxis against Aspergillus species should be considered in patients with past history of aspergillosis or colonization of Aspergillus species, at facilities with high incidence of IA and those without a protective environment. Early diagnosis and prompt antifungal treatment is important to improve outcome. Imaging studies such as computed tomography and biomarkers such as galactomannan antigen and β-D-glucan are useful for early diagnosis. Empirical antifungal treatment based on persistent or recurrent fever during neutropenia despite broad-spectrum antibiotic therapy is generally recommended in high-risk patients. Alternatively, a preemptive treatment strategy has recently been proposed in the context of progress in the early diagnosis of IA based on the results of imaging studies and biomarkers. Voriconazole is recommended for initial therapy for IA. Liposomal amphotericin B is considered as alternative initial therapy. Combination antifungal therapy of echinocandin with voriconazole or liposomal amphotericin B could be a choice for refractory cases.
authors.affiliation: Division of Hematology, Saitama Medical Center, Jichi Medical University.
authors.forename: Shun-Ichi
authors.initials: S
authors.lastname: Kimura
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage; D000935:Antifungal Agents / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000009:adverse effects; D001228:Aspergillosis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D015415:Biomarkers / Q000032:analysis; D054714:Echinocandins / Q000008:administration & dosage; D019337:Hematologic Neoplasms / Q000150:complications* / Q000628:therapy; D006801:Humans; D009503:Neutropenia / Q000209:etiology; D009894:Opportunistic Infections / Q000150:complications* / Q000188:drug therapy* / Q000517:prevention & control; D012307:Risk Factors; D033581:Stem Cell Transplantation / Q000009:adverse effects; D014057:Tomography, X-Ray Computed; D065819:Voriconazole / Q000008:administration & dosage
chemical_list: D000935:Antifungal Agents; D000970:Antineoplastic Agents; D015415:Biomarkers; D054714:Echinocandins; D000666:Amphotericin B; D065819:Voriconazole